Evidence map›Paper›PMID 28398822›Full record

ArticleAntioxidants & redox signaling2018

A Peroxidase Peroxiredoxin 1-Specific Redox Regulation of the Novel FOXO3 microRNA Target let-7.

Barbara L Hopkins, Monica Nadler, John J Skoko, Thierry Bertomeu, Andrea Pelosi, Parisa Mousavi Shafaei, Kevin Levine, Anja Schempf, Bodvael Pennarun, Bo Yang and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Antioxidants & redox signaling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. FOXO transcription factors as mediators of stress adaptation.Nature reviews. Molecular cell biology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Let-7 underlies metformin-induced inhibition of hepatic glucose production.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Barbara L Hopkins1 Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh , Pittsburgh, Pennsylvania.
Monica Nadler3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
John J Skoko2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Thierry Bertomeu3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Andrea Pelosi4 Oncogenomic and Epigenetic Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area Regina Elena National Cancer Institute , Rome, Italy .
Parisa Mousavi Shafaei2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Kevin Levine2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Anja Schempf2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Bodvael Pennarun3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Bo Yang5 Department of Pharmaceutical Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania.
Dipak Datta3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Octavian Bucur3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Kenneth Ndebele3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Steffi Oesterreich2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Da Yang5 Department of Pharmaceutical Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania.
Maria Giulia Rizzo4 Oncogenomic and Epigenetic Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area Regina Elena National Cancer Institute , Rome, Italy .
Roya Khosravi-Far3 Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center , Boston, Massachusetts.
Carola A Neumann2 Department of Pharmacology and Chemical Biology, Magee Womens Research Institute, University of Pittsburgh Cancer Institute , Pittsburgh, Pennsylvania.
Harvard University · USUniversity of Pittsburgh · USBeth Israel Deaconess Medical Center · US

Funding

Combination FGFR4 and ER-Targeted Therapy for Invasive Lobular CarcinomaF30CA203154 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, KEVIN MAX · 2017 to 2020
$170k
NCI NIH HHS F30 CA203154
6 · The paper itself

Abstract

Precision in redox signaling is attained through posttranslational protein modifications such as oxidation of protein thiols. The peroxidase peroxiredoxin 1 (PRDX1) regulates signal transduction through changes in thiol oxidation of its cysteines. We demonstrate here that PRDX1 is a binding partner for the tumor suppressive transcription factor FOXO3 that directly regulates the FOXO3 stress response. Heightened oxidative stress evokes formation of disulfide-bound heterotrimers linking dimeric PRDX1 to monomeric FOXO3. Absence of PRDX1 enhances FOXO3 nuclear localization and transcription that are dependent on the presence of Cys31 or Cys150 within FOXO3. Notably, FOXO3-T32 phosphorylation is constitutively enhanced in these mutants, but nuclear translocation of mutant FOXO3 is restored with PI3K inhibition. Here we show that on H

Indexed as

Gene Expression RegulationOxidation-ReductionRNA InterferenceBinding SitesCell LineCell MovementDisulfidesForkhead Box Protein O3HumansMicroRNAsModels, BiologicalOxidative StressPeroxiredoxinsPromoter Regions, GeneticProtein BindingProtein TransportDisulfidesForkhead Box Protein O3FOXO3 protein, humanMicroRNAsmirnlet7 microRNA, humanPeroxiredoxinsPRDX1 protein, humanbreast cancerFOXO3let-7oxidative stressPRDX1tumor suppressor

Identifiers

PMID28398822
PMCPMC5695745
OpenAlexW2589915638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.